Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV003371177 | SCV004086249 | uncertain significance | Inborn genetic diseases | 2023-07-14 | criteria provided, single submitter | clinical testing | The c.1652C>T (p.S551L) alteration is located in exon 12 (coding exon 11) of the CAPN5 gene. This alteration results from a C to T substitution at nucleotide position 1652, causing the serine (S) at amino acid position 551 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003778044 | SCV004675914 | uncertain significance | not provided | 2022-11-12 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 551 of the CAPN5 protein (p.Ser551Leu). This variant is present in population databases (rs782766470, gnomAD 0.06%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with CAPN5-related conditions. |